Decreased METTL3 expression increased the sensitivity of Hela cells to cisplatin, and increased METTL3 expression in bladder cancer cells increased the resistance of bladder cancer cells to cisplatin [12,19]. The gene discussed is METTL3; the disease is urinary bladder carcinoma.